US 12404318
Combination HBV therapy
granted A61KA61K2039/505A61K2039/545
Quick answer
US patent 12404318 (Combination HBV therapy) held by Vir Biotechnology, Inc. expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Vir Biotechnology, Inc.
- Grant date
- Tue Sep 02 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/545, A61K31/522, A61K31/675